

Index

a

acceptor-labelled micelles (ECCM) 220, 221
 acetan 64, 65
 acetic acid bacteria (AAB) 150, 165
 acetyl-CoA 77, 233, 236
 acrylamide monomer (AM) 142, 157
 acute toxicity 12, 22, 304, 305
 Alexa Fluor 555-labeled streptavidin (AF555-Streptavidin) 217
 algae cultivation 32
 algal EPS (sEPS) 33, 36, 39
 Algenist™ 40
 alginates 67–68, 70, 80, 81, 86, 136, 137, 289
 α scaffolds 271
 alternan 69, 72, 106, 120
 amphiphilic hydrophobin proteins 166
 ampholytic hydrogels 27
 amyloid fibrils (AF) 214, 216
 amyloid-HA bone biomimetic composites 214
 amyloid-like proteins 216
 amyloid protein nanofibrils 209, 214, 232
 anaerobic bacteria 103
 anhydroglucose units (AGU) 138, 139
 anionic hydrogel 27
 anticoagulant activity of macroalgal polysaccharides 38
 antihuman immunodeficiency virus (HIV) 36
 anti-inflammatory activity 37–38
 antiproliferative 37
 antiviral activity 36, 117

articular cartilage 192, 193, 286
 artificial lubricant 193
 ATP-binding cassette (ABC) transporter-dependent mechanism 72
Aureobasidium pullulans 20, 22, 66
 Avicel® 139

b

bacterial cellulose 149, 151, 284, 285
 bacterial exopolysaccharides 85
 bacterial nanocellulose (BNC) 149–151, 163, 164
 bacterial polysaccharides
 active precursor 71–72
 alginate and cellulose 73
 ATP-binding cassette (ABC) transporter-dependent mechanism 72
 c-di-GMP 75
 extracellular synthesis 72
 genetic background 70–71
 polymerization 71–72
 regulatory RNA binding proteins 75
 sRNAs regulatory networks 74
 synthase-dependent mechanism 72
 Wzx/Wzy-dependent mechanism 71–72
Bacteroides 105, 118
 beneficial bacteria 117–119
 1,4- β -D-glucose backbone 23
 β -D-glucuronic acid 68
 β -D-N-acetyl-glucosamine 68
 β scaffolds 270, 271

- biobased polymers
 - for biomedical applications
 - alginate 136, 137
 - biomaterials 132–135
 - chitin 137
 - poly(butylene succinate) 136
 - polyhydroxyalkanoates 136
 - polylactide 135
 - starch 136
 - synthetic/naturally occurring 135
 - biomedical engineering 130–132
 - first generation of 129
 - global production of 129
 - principal 129
 - biocompatibility
 - biopolymeric materials and devices 2–4
 - concept and definition of 1
 - cytotoxicity 11–12
 - implantation 14–15
 - risk based approach
 - chemistry screening of biopolymers 7–11
 - factors 5
 - PCL pipeline upstream 5
 - polyesters 7
 - polysaccharides 6
 - proteins 7
 - systemic toxicity 12–14
 - biocompatible 4
 - fibrous proteins 209
 - hydrogel 29
 - Biofill® 163, 164
 - biological polymers 30
 - biomaterials
 - cellulose 138
 - ceramics 132
 - definition 132
 - metals and metal alloy 132
 - nature derived polymers 135
 - petroleum derived polymers 134
 - synthetic polymers 134, 135
 - biomedical engineering 130–132, 135, 182, 190, 215–216
 - bionanocomposites 29–32, 44
 - biopolymers
 - biocompatibility evaluation of 2–4
 - chemistry of 6–7
 - chemistry screening of 7–11
 - cytotoxicity of 11–12
 - FucoPol 30
 - implantation 14–15
 - microbial polysaccharides 22–25
 - systemic toxicity 13
 - Biopreferred® program 129
 - Bioprocess® 164
 - Blue Lagoon ecosystem 38
 - bone tissue engineering 164, 165, 213–215, 276, 287–289
 - bovine serum albumin (BSA) 211
 - bovine submaxillary mucin MUC5B (BSM) 182
 - Brownian motion 189
 - 1,4-butanediol (BDO) 136
- C**
- calcium-alginate gels 137
 - cancer therapy, pullulan 22–23
 - capsular polysaccharides (CPS) 19, 72, 73, 82, 103
 - carbon nanofibers (CNFs) 218
 - carbon nanotubes (CNT) 22, 29, 30, 154, 211, 362
 - carboxymethylcellulose (CMC) 142, 192
 - cationic hydrogel 27
 - CdSe-ZnS quantum dots 216
 - cell-bound mucins 185
 - cellobiose 138, 148, 149
 - cell-permeating peptides (CPPs) 274–276
 - cellulose 67
 - anhydroglucose units 138
 - cell wall of plants 138
 - chemical and physical structure 138
 - chemical modification of 141
 - drug tableting industry 141
 - esters 141
 - hydrogels of 142
 - industrial scale use of 139
 - intra- and interchain hydrogen bonding 138
 - microcrystalline cellulose 139
 - medical uses of 142

- microfibers and wood fibers 140
 - polymerization degree of 138
 - wood 138
 - cellulose acetate phthalate (CAP) 141
 - cellulose microfibrils 143, 145
 - cellulose nanocrystals (CNC)
 - 142–145, 154
 - cellulose nanofibrils (CNF) 142, 143
 - biodurability of 163
 - enzymatic pre-treatment 146–148
 - general procedures 146
 - genotoxicity of 156
 - health and environmental safety 154
 - high energy consumption 146
 - industrial production of 146
 - mechanical treatment devices 146, 147
 - medical applications 164–169
 - TEMPO mediated oxidation
 - pre-treatment 148–149
 - terminology 145
 - toxicological assessment of 157
 - wood and annual plants 146
 - cellulosic nanomaterials (CNMs) 151
 - characterization of 151–153
 - health and toxicology 154–163
 - cellulosics 44, 141–146, 149, 154
 - ceramics 29, 132, 134, 357
 - cetyltrimethylammonium bromide (CTAB) 163
 - chemically crosslinked hydrogels 26
 - chitin 137
 - advantage 40
 - biomedical 42
 - deacetylation reaction of 40
 - fungal 41
 - microbial 40
 - textile industry 44
 - chitin–glucan complex (CGC) 41–44
 - chitinous polysaccharides
 - biomedical 42–43
 - food applications 43
 - metals absorption capacity of 44
 - pharmaceutical applications 43
 - properties and applications 41, 42
 - chitosan (CN) 137, 282–284, 285–287
 - biomedical field 42
 - cosmetic products 43
 - deacetylation reaction of 40
 - food preservation 43
 - hydrogels 27
 - properties of 41, 42
 - chitosan–glucan complex (ChGC) 41, 42
 - Chlorophyta 33
 - chronic toxicity 13
 - Chrysophyta 33
 - Clostridia 118
 - collagen 43, 129, 137, 209, 213, 267, 269, 276, 277, 279, 284–287, 358, 360, 361
 - collagen-binding peptides (CBPs) 274
 - commercial microalgae products 33
 - commercial mucins 183
 - core-crosslinked micelles (CCMs) 220
 - crosslinker 26, 163, 168, 214, 359
 - curdlan 24, 64, 67, 72, 78, 85
 - cyclic-3'5'-diguanylic acid (c-di-GMP)
 - 75, 76, 81, 86
 - cyclic peptides (CPs) 270, 273, 276
 - cysteine-rich regions 185
 - cytotoxicity 11–12, 83, 154, 156–163, 190, 216, 285
- d**
- database of PS 111
 - deacetylated gellan 27
 - deacetylation degree (DD) 41
 - degenerative diseases 209
 - degree of mucin aggregation 189
 - degree of polymerization (DP) 67
 - cellulose nanofibrils 148
 - galacto-oligosaccharides 118
 - dendritic cells (DCs) 36, 160
 - design of donor-labelled SP1 (DSP1)
 - 220
 - detrimental bacteria 117
 - dextran (Dex) 20, 22, 24, 28, 32, 68–69, 72, 106, 107, 111, 267, 268, 282
 - dextranucrase genes 111
 - dietary fibers 43, 69, 118, 119
 - diguanylate cyclases (DGC) 75
 - dimethyl succinate 136

diutan 66, 72
 doxorubicin (DOX) 215, 269
 drug delivery 131, 280–284
 hydrogels components of 194
 targeted 273, 274
 vehicles 267–273

e

ectromelia virus (ECTV) 36
 elastin-like polypeptides (ELPs) 272,
 276–278
 electrospinning 210–212, 222, 223,
 286, 358, 360–362, 368, 371,
 376
 electrospun fibrous protein membranes
 222
 electrospun protein nanofibers 218
 electrospun SF nanofiber membranes
 221
 engineered mucins 194–195
 engineering polysaccharide-producing
 cell factories
 controlling processivity via copy
 number of polymerase/synthase
 82
 controlling processivity via coupling
 with modification events 80
 controlling processivity via substrate
 concentration 82
 controlling processivity via substrate
 tethering mechanism 80
 controlling processivity via Wzz
 protein and homologues 81
 generally regarded as safe 76, 77
 genetic and metabolic pathways
 78–79
 processive or non-processive
 mechanisms 80
 production 77
 recombinant production
 alginate 86
 bacterial exopolysaccharides 85
 cellulose and hyaluronate 84,
 85
 gram-negative bacteria 84
 heterologous hosts 86
 nonpathogenic 84

 nonvirulent 84
 toxin-free cell factories 84
 enzyme-linked immunosorbent assay
 (ELISA) 194
 epidermal and dermal wounds 137
 eukaryotic organisms 33
 European Medicines Agency (EMA) 8
 European SUNPAP project 154
 exopolysaccharides (EPS) 19, 33, 66,
 70, 75, 84, 103–104
 exotoxins 83
 extracellular matrix (ECM) 130, 277,
 357
 extracellular polymeric substances (EPS)
 76, 150

f

fabricate hydrogels 28
 fecal bifidobacteria 118
 fibrin 267, 276, 363, 364
 fibrous proteins
 advantages 209
 biocompatible 209
 biomedical engineering 215–216
 bone tissue engineering 213–215
 characterizations 213
 energy application 218–220
 environmental application 220–222
 formation of 209
 molecular self-assembly 209
 nanodevices 217–218
 sensors and biosensors 216–217
 structure 212–213
 synthesis methods 210–212
 electrospinning 210–212
 self-assembly of biomolecules 211
 solution blowing 210, 211
 template-assisted synthesis 211
 fluorescently labeled mucins 189
 food for specified health use (FOSHU)
 system 119
 fructo-oligosaccharides (FOS) 117
 FucoPol 22, 30
 fucose 19–21, 30, 33, 78
 functional mucin glycoproteins
 183
 fungal chitin 41

g

galacto-oligosaccharides (GOS)
117–119
galactoglucan 64–66
Gal–Gal linkage 118
gastric/intestinal mucins 183
gastrointestinal microflora 117
gelatine 267, 269, 276, 286, 289, 359,
361, 363–367, 370–372
gel electrophoresis 187, 188
gel-forming mucins 185
gellan 22, 25, 27, 64, 66, 72
gellan gum 22, 24–27, 32, 267, 288
gellan hydrogels 27
generally recognized as safe (GRAS)
25, 76, 115
glucans 20, 24, 105–107
glucuronic acid 19–21, 23, 25, 64–66
glycogen 19, 63
glycoproteins 181–187, 189–190, 193,
195
glycosyltransferases 70–73, 75, 76, 79,
80, 105, 111, 119
gram-negative bacteria 84, 85, 105
GrowDex® 164
gut microbiome 181

h

Hayashibara Co., Ltd. (Japan) 23
headspace gas chromatography with
mass spectroscopy (HS-GC/MS)
9
herpes simplex virus types 1 (HSV-1)
36
hetero-PS
biosynthesis 111, 112
instability production of 116–117
monosaccharides composition of
111–112
monosaccharides, types of 104
yield of 112–116
heteropolymers 64, 66, 67, 71, 72, 82
high-performance liquid
chromatography (HPLC) 166,
188
high-resolution accurate mass (HRAM)
10

homofermentation 103
homo-PHAs
improved microbial production of
243–245
integrated production process of
246–247
material properties of 245–246
medium-chain-length PHA
monomeric constituents
240–241
pathway engineering for 242–243
homopolymers 23, 26, 64, 67, 72, 232,
233, 242–244, 246, 253
homo-PS
biosynthesis of 104–105
composition and structure 106
glucansucrase or levansucrase 104
instability production of 106–111
single type of monosaccharide 104
human cytomegalovirus (HCMV)
36
human herpes virus type 6 (HHV-6)
36
human mucin sources 183
hyaluronate 68
hyaluronic acid (HA) 3, 7, 20, 22, 25,
26, 28, 29, 39, 68, 72, 77, 78, 191,
192, 267, 268, 281, 282, 287–289,
358, 359
hydrogels
chemically crosslinking agent 26
chitosan 27, 28
definition 25
dextran 28
fabrication of 27
homopolymer 26
interpenetrating polymeric network
26
physically crosslinking agent 26
polysaccharide 27
of pullulan 23
semi-IPN 26
smart/stimuli-sensitive 27
3D crosslinked polymeric network
25
xanthan gum 28
hydrophobic drugs 30, 166, 270

hydroxyapatite (HA) 137, 213, 272,
286, 365
hydroxyethylcellulose (HEC) hydrogels
142
hydroxyethyl-methacrylate-derivatized
dextran (Dex-HEMA) 28
hydroxymethylpropylcellulose (HPMC)
141

i

Implantation, biopolymers 14–15
influenza A virus 36
International Conference on
Harmonization (ICH) 8
International Union of Pure and Applied
Chemistry (IUPAC) 130
interpenetrating polymeric network
(IPN) hydrogels 26
inulin 69, 72, 106, 110, 117,
120
ionic hydrogel 27
ISO 10993 1, 12
isothermal titration calorimetry (ITC)
166

j

jellyfish mucins 183

k

KNK-005, genotype of 238

l

L929 mouse fibroblast cell line 11
lactate-polymerizing enzyme (LPE)
biosynthesis 249–251
creation of 247–248
integrated production process
251–252
properties 253–254
lactic acid bacteria (LAB)
biofilm inhibition activity 105
definition 103
exopolysaccharides 103–104
health benefits 105
hetero-PS
biosynthesis 111, 112
instability production of 116–117

monosaccharides composition of
111–112

monosaccharides, types of 104
sugar transportation 104
yield of 112–116

homo-PS

biosynthesis of 104–105
composition and structure 106
glucanucrase or levansucrase
104

instability production of
106–111

single type of monosaccharide
104

polysaccharides 105, 118–119
prebiotics

definition 117
dietary fiber 119
in Japanese FOSHU 119
oligosaccharides 117–119
rheological effects of 105

Lead Market Initiative (LMI) 129

levan 25, 69, 72, 106, 109

liver tissue engineering 137

low critical solution temperature
(LCST) 27–28

lyophilisation 184, 185

m

macroalgal 38, 39

macrophage activation 37

mannan 111, 112

measles virus 36

medium-chain-length PHAs
(mcl-PHAs) 240–242

MEM Elution 11

metallic nanoparticles (MNPs) 29, 30

metals and metal alloy biomaterials
132

microalgae

biological activity and potential
applications 33–39

commercialization 39–40

growth requirements 32

polysaccharide-producing microalgae
33

production 32, 33

- microalgae polysaccharides
 - bioactive properties
 - anticancer activity 36–37
 - anticoagulant/antithrombotic activity 38
 - anti-inflammatory activity 36–37
 - antioxidant activity 38–39
 - antiviral activity 36
 - immunomodulatory activity 36, 37
 - sulfated polysaccharides 39
 - biomedicine 44
 - cosmetics 44
 - exploitation of 39
 - nutraceuticals 44
 - pharmaceuticals 44
 - polysaccharide-producing microalgae 33
 - microbes 63, 76
 - microbial celluloses 67, 84
 - microbial chitin 40–42
 - microbial chitosan 27
 - microbial polysaccharides
 - acetan 64
 - alginates 67–68
 - application 19
 - biological activities 20
 - bionanocomposites 29–32
 - biopolymers 22
 - biosynthesis pathways of bacterial polysaccharides 69–76
 - carbohydrates 20
 - cellulose 67
 - curdlan 24, 67
 - definition 19
 - dextrans 20, 24, 68–69
 - engineering
 - polysaccharide-producing cell factories 76
 - galactoglucan 64–66
 - gellan gum 24, 27
 - hyaluronate 68
 - hyaluronic acid 20, 25, 68
 - hydrogels 25
 - inulines 69
 - levan 25, 69
 - properties of 20
 - pullulan 20, 22, 66
 - scleroglucan 20, 23
 - sphingan 66
 - succinoglycan 64–66
 - xanthan 20, 64
 - xanthan gum 23
 - microbial protein nanofibers 218
 - microcrystalline cellulose (MCC) 139, 154
 - microfibrillated cellulose (MFC) 143, 145, 153
 - microscale thermophoresis 188, 189
 - misfolded protein aggregation 209
 - modified pullulan 22
 - molecular lubricant 185, 189, 190
 - monomer peptides 277
 - mouth sprays 192
 - MTT/XTT assays 11
 - mucin glycoproteins 182–184, 186, 187, 195
 - mucin-mimetic polymers 194–195
 - mucins
 - atomic force microscopy 189
 - of biomedical engineering 182
 - in breast milk 181
 - engineered and mucin-mimetic polymers 194–195
 - gel electrophoresis 187
 - in human body 182
 - light scattering techniques 189
 - mechanical characterization method 189
 - molecular weight of 187
 - mucus systems 181
 - physiological processes 181
 - of pigs and cows 183
 - purified 190
 - sources and purification process 182
 - structure–function relation 185–187
 - multi-domain peptides (MDPs) 280
 - mumps virus 36
 - mutan 69, 72, 106, 107
- n**
- nano life cycle risk assessment (nanoLCRA) 156

- nanocellulose
 - bacterial nanocellulose 149–151
 - cellulose nanocrystals 142, 144–145
 - cellulose nanofibrils 142, 145–149
 - cellulosic nanomaterial 151–153
 - characteristics of 143
 - drawback for 143
 - industrialization of 153–154
 - isolation and characterization of 143–151
 - natural and renewable polymer 142
 - traditional cellulose-derived products 143
- nanocomposites 29–31, 220
- nanofibrillated cellulose (NFC) 143, 145, 153
- nanofibrous protein materials 222
- natural polypeptides 269
- naturally occurring polymers 135
- nature derived polymers 135
- Naviculan 36
- neural stem cells (NSCs) 279
- neutral red uptake assay 11
- nonmammalian mucin sources 183
- non-volatile organic compounds (NVOCs) 9, 10
- nylon filtration 214
- O**
- oil industry 23
- oligosaccharides 19, 24, 79, 82, 117–119, 267, 281
- orbitrap 10
- organized protein self-assembly 209
- osteoarthritis 25, 192, 193, 278, 284
- osteogenesis biomaterials 214
- oxidative stress 38, 163, 289
- oxygen reduction reaction (ORR) 219
- P**
- palm kernel fatty acid distillate (PKFAD) 246
- particulate matter (PM) 222
- PEDOT-S coating 217, 218
- pentacosadiynoic acid (PCDA) 216
- peptides
 - amphiphiles 271–272
 - collagen-binding peptides 274
 - cyclic peptides 270, 273, 276
 - monomer 277
 - multi-domain peptides 280
 - in regenerative medicine 276–280
 - in tissue engineering 276–280
- petroleum derived polymers 134
- PHBH
 - chemical structure of 234
 - DSC analysis of 235
 - fermentative production of 234
 - industrial production process of 235, 236
 - industrialization 239
 - material properties of 234
 - producing bacteria, molecular breeding of 236, 237
 - synthesis pathway 237
- photosynthetic organisms 32
- physically cross-linked hydrogels 26
- PilA 218
- plant cellulose 150, 284, 285
- poly(A)₁₅ DNA 217
- poly(butylene succinate) (PBS) 129, 136
- polycaprolactone (PCL) implant 3, 5, 134, 231, 286, 361
- polyhydroxybutyrate (PHB) 136
- polyelectrolytes 20, 27, 269, 284
- poly(3,4-ethylenedioxythiophene) (PEDOT) 217
- polyethylenimine (PEI) 163, 278
- poly(3-hydroxybutyrate-co-3-hydroxyhexanoate) 232–234
- polyhydroxyalkanoates (PHAs) 136, 231
 - chemical structure of 232
 - physicochemical and thermal properties of 241
- polylactic acid (PLA) 3, 7, 13, 129, 135, 281, 362
- polylactide (PLA) 231
- polymeric carbohydrates 63
- polymerization degree (DP) 79–83
- polysaccharide-based nanomaterials 31
- polysaccharide hydrogels 27, 265

polysaccharide-producing microalgae
33, 34, 35

polysaccharides
fabrication techniques 285
lactic acid bacteria 129
structures of 268

porcine gastric mucin (PGM) 182
Porphyridium cruentum 33, 34,
36

prebiotic LAB
definition 117
in Japanese FOSHU 119
oligosaccharides 117–119
polysaccharides 118

prokaryotic organisms 33, 70, 74,
76

pullulan 20, 22–23, 66, 82, 267

purge and trap GC/MS 9

purified mucins
biomedical applications
animal tissue samples 190
artificial joint fluids 192–193
clinical evaluation of 194
coating 193
eye drops/contact lens coatings
190–191
high-quality mucin 190
hydrogels for drug delivery 194
mouth sprays 192

Pyrrophyta 33, 34

q

quantitative time of flight (qTOF) 10
quartz crystal microbalance (QCM)
189

r

Ralstonia eutropha 232, 238–239
reduced graphene oxide (RGO) 220
regenerative medicine 137
peptides in 276–280
tissue engineering 137, 276–280,
284–289

rhamnan 64, 66

Rhodophyta 33, 34

ring-opening polymerization (ROP) 7,
247

s

scleroglucan 20, 22, 23

secreted gel-forming mucins 185

secreted non-gel-forming mucins 185

self-assembled fibrous protein scaffolds
220

semi-volatile organic compounds
(SVOCs) 9, 10

SF/PEO membranes 222

silylated hydroxypropylmethyl-cellulose
hydrogels 142

silk-elastin-like protein polymer (SELP)
216

silk fibrils 214–216

silk fibroin (SF) 209, 214, 267, 269,
270, 286, 362

silk nanofiber network-based
bio-triboelectric generator
(Silk Bio-TEG) 220

silk protein 210, 211, 220, 222

small noncoding RNAs (sRNA) 74

smart/stimuli-sensitive hydrogels 27

sodium-carboxymethylcellulose
(Na-CMC) 142

solution blowing 209–211, 223

sphinganol polysaccharides 66, 72

Sphingomonas sanxanigenens 66

stable protein one (SP1) 220

standard biocompatibility test 13

starch 22, 28, 29, 135, 136, 239, 286

Streptococcus zooepidemicus 20, 25, 82

subacute toxicity 4, 12

subchronic toxicity 4, 12

succinoglycan 64–66, 72

sulfated polysaccharides 36, 38, 39

sulfur-containing EPS 36

synthase-dependent mechanism 72

synthetic and natural substrates 267
cell-permeating peptides 274–276
drug delivery vehicles 267–273
polysaccharides applications 280,
289

regenerative medicine 276–280

targeted drug delivery 273–274

tissue engineering 276–280

synthetic biopolymers 135, 267, 286,
287

synthetic peptides 270, 271, 278, 280
 synthetic polymers 2, 30, 134, 135,
 139, 193, 278, 281, 358
 synthetic polypeptides 270–280
 systemic toxicity 4, 8, 11–14, 283

t

tailor-made products 70, 83–86, 251
 targeted drug delivery 273, 274
 template-assisted synthesis 209, 211
 TEMPO mediated oxidation
 pre-treatment 146, 148–149
 tetrodotoxin 105
 thermostable biopolymer 23
 tissue engineering 130, 131
 bone 164, 213–215
 drug delivery *see* drug delivery
 liver 137
 peptides in 276–280
 regenerative medicine 137,
 276–280, 284–289
 tobacco mosaic virus (TMV) 220
 toxicological concern (TTC) 8
 tribological shear stress 187
 two-component systems (TCS) 74
 type III secretion system (T3SS) 84

u

UDP-glucose 71, 78
 UDP-*N*-acetylglucosamine 78, 82,
 85
 ultrasmall peptides 269–270
 upper critical solution temperature
 (UCST) 27

Ure2-alkaline phosphatase (Ure2-AP)
 212, 285
 US Department of Agriculture (USDA)
 129
 US Food and Drug Administration
 (FDA) 8, 70, 76, 80

v

vaccinia virus (VACV) 36
 vascular graft prostheses design 134
 volatile organic compounds (VOCs) 9
 von Willebrand factor-like domains
 185

w

welan 66, 72
 wide-angle X-ray diffraction (WAXD)
 245
 wound healing 24, 27, 42, 43, 130, 137,
 164, 165, 167, 170, 191, 194, 265,
 370

x

xanthan 20, 23, 24, 26, 28, 64, 71–73
 xanthan-based polymers 24
 xanthan gum 22–24, 28, 29, 32, 39, 64,
 115, 267, 284
Xanthomonas campestris 23, 64, 112
 XCell® 164
 xerostomia 192
 xylo-oligosaccharides 118

z

zero-order kinetic release rate 132